Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Short-term Investments (2022 - 2025)

Historic Short-term Investments for Agilon Health (AGL) over the last 4 years, with Q3 2025 value amounting to $139.2 million.

  • Agilon Health's Short-term Investments fell 4314.16% to $139.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.2 million, marking a year-over-year decrease of 4314.16%. This contributed to the annual value of $211.7 million for FY2024, which is 4439.29% down from last year.
  • Per Agilon Health's latest filing, its Short-term Investments stood at $139.2 million for Q3 2025, which was down 4314.16% from $155.6 million recorded in Q2 2025.
  • In the past 5 years, Agilon Health's Short-term Investments registered a high of $422.5 million during Q1 2023, and its lowest value of $139.2 million during Q3 2025.
  • Moreover, its 4-year median value for Short-term Investments was $299.5 million (2024), whereas its average is $305.3 million.
  • Per our database at Business Quant, Agilon Health's Short-term Investments surged by 3622.54% in 2023 and then crashed by 4664.84% in 2025.
  • Over the past 4 years, Agilon Health's Short-term Investments (Quarter) stood at $411.9 million in 2022, then fell by 7.56% to $380.8 million in 2023, then crashed by 44.39% to $211.7 million in 2024, then plummeted by 34.27% to $139.2 million in 2025.
  • Its Short-term Investments stands at $139.2 million for Q3 2025, versus $155.6 million for Q2 2025 and $230.1 million for Q1 2025.